Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Up 117.2% in June

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 126,421 shares, a growth of 117.2% from the June 15th total of 58,214 shares. Approximately 5.1% of the shares of the stock are sold short. Based on an average daily volume of 76,377 shares, the short-interest ratio is currently 1.7 days.

Intensity Therapeutics Price Performance

Shares of INTS traded up $0.04 during mid-day trading on Wednesday, hitting $4.92. 20,734 shares of the stock were exchanged, compared to its average volume of 46,246. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.86 and a current ratio of 4.86. The company has a market cap of $13.27 million, a PE ratio of -0.86 and a beta of 2.78. Intensity Therapeutics has a 52-week low of $3.51 and a 52-week high of $43.50. The firm has a 50-day moving average of $4.36 and a two-hundred day moving average of $6.45.

Intensity Therapeutics (NASDAQ:INTS) last posted its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. On average, equities analysts predict that Intensity Therapeutics will post -2.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on INTS. Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.50.

Institutional Investors Weigh In On Intensity Therapeutics

Several institutional investors have recently modified their holdings of INTS. Geode Capital Management LLC boosted its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after buying an additional 201,357 shares during the period. Corient Private Wealth LLC bought a new position in Intensity Therapeutics during the 4th quarter valued at about $41,000. State Street Corp raised its position in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the period. Jane Street Group LLC purchased a new stake in Intensity Therapeutics in the 4th quarter worth about $26,000. Finally, Mesirow Financial Investment Management Inc. grew its stake in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after buying an additional 51,000 shares during the last quarter. 3.74% of the stock is owned by institutional investors.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.